title: Global Forum on TB Vaccine Research and Development. World Health Organization, June 7-8 2001, Geneva.
abstract: The TB community now envisions a turning point in the development of improved TB vaccines for both high and low incidence countries. With a number of viable TB vaccine candidates now available for testing, the investigation of safety and immunogenicity in human clinical trials is seen as the driving force for the future development of effective vaccines for the prevention of tuberculosis.
authors.affiliation: Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA. brennan@cber.fda.gov
authors.forename: M J
authors.initials: MJ
authors.lastname: Brennan
authors.forename: U
authors.initials: U
authors.lastname: Fruth
mesh_terms: D001500:BCG Vaccine; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007373:Interinstitutional Relations; D012106:Research; D014376:Tuberculosis / Q000517:prevention & control*
chemical_list: D001500:BCG Vaccine